{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'treatment for the prevention of HAE attacks in Part 1 of the BCX7353-302 study, with better', 'efficacy at the 150 mg dose compared to the 110 mg dose, and no increase in safety risk.', 'As a result of these safety and efficacy findings in Study BCX7353-302 indicating a more', 'favorable benefit: risk profile for 150 mg QD, all subjects in Studies BCX7353-302 and', 'BCX7353-204 are being transitioned to a 150 mg QD dose after a year of either 110 or 150 mg', 'QD (ie, completion of Parts 1 and 2). Because the steady-state exposure of BCX7353 in Western', 'subjects is similar to Japanese subjects (Investigator Brochure), the DMC has identified no safety', 'issues in this ongoing study, and the current study is not sufficiently powered on its own to detect', 'a treatment difference between placebo and BCX7353, subjects in Study BCX7353-301 will be', 'similarly transitioned to 150 mg QD after 1 year of treatment (ie, completion of Parts 1 and 2),', 'when they enter Part 3 of the study.', '5.4.3.', 'Rationale for Study Population', 'The current study is limited to adults and adolescents (> 12 years of age) of both sexes with HAE', 'Type 1 and 2. Children < 12 years of age are excluded from participation in BCX7353 clinical', 'trials until the benefit-risk profile in adults and adolescents has been better characterized. It is', 'anticipated that exposure in adolescent subjects will not exceed safe and tolerable exposures in', 'adults.', 'Based on past and ongoing studies conducted in subjects with HAE, it is anticipated that female', 'subjects will comprise at least 50% of the subject population. HAE affects both males and', 'females, although the disease has a greater burden on females, with an increased frequency and', 'severity of HAE attacks in women (Bork, Meng et al. 2006, Lumry, Castaldo et al. 2010).', 'Estrogen appears to worsen the disease, as evidenced by an increased number of attacks reported', 'following onset of puberty and when estrogen-containing therapy is initiated (Bouillet,', 'Longhurst et al. 2008, Caballero, Farkas et al. 2012). Due to the gender distribution of HAE and', 'the influence of hormones on the frequency of attacks, it is considered important to include both', 'male and female subjects in this clinical study to gain an assessment of potential safety and', 'population PK differences.', 'Although there is no evidence of embryofetal developmental toxicity with BCX7353 in', 'reproductive toxicology studies (Section 5.2), appropriate precautions are still warranted with', 'respect to administration of BCX7353 to women of reproductive age, in accordance with', 'International Council for Harmonisation (ICH) guidelines. Women of childbearing potential may', 'be enrolled in this trial provided they meet the contraceptive requirements and have a negative', 'pregnancy test (Section 8.2.1).', 'Pregnant women will be excluded from participation in the current study. Additionally, any', 'female subject who becomes pregnant on study will be required to immediately discontinue', 'study drug and will be followed through the end of the pregnancy (see Section 12.1.6).', 'Breastfeeding women will also be excluded from this study.', '5.4.4.', 'Rationale for Control Group and Prohibition of Current Prophylactic', 'Medications', 'In the current study, all participants must have access to an effective, approved treatment for', 'attacks or episodes of angioedema as part of their routine medical care. Each subject will', 'continue to use his or her prescribed acute medication to treat attacks, under the medical', '33']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'management plan advised by his or her physician, throughout the study. This is consistent with', 'guidance documents that strongly support the position that all subjects with C1-INH deficiency', 'should have access to medications for treating attacks (Cicardi, Bork et al. 2012, Zuraw, Banerji', 'et al. 2013).', 'While in some countries (not including Japan) there are approved therapies for prophylaxis', 'against HAE attacks, such as C1-INH, consensus recommendations do not exist for either', 'prophylactic treatment as a standard of care or a definition of indications for prophylaxis.', 'The International World Allergy Organization/European Academy of Allergy and Clinical', 'Immunology guidelines for the management of HAE recommends prophylaxis be considered for', 'patients who \"face events in life that are associated with increased disease activity,\" specifically', 'C1-INH for first-line, long-term prophylaxis (Maurer, Magerl et al. 2018). Given the lack of', 'wide availability of such a treatment in Japan and the limitations of intravenous (IV) therapy, a', 'study of an orally available product such as BCX7353 is appropriate.', 'A subject randomized to placebo in the current study who has access to effective attack', 'medications is therefore considered to be treated in line with current guidelines.', 'Unapproved prophylactic therapies may be used by some HAE patients in Japan. To guard', 'against enrolling subjects who need prophylaxis, subjects must meet an inclusion criterion', 'assessing whether they are medically appropriate for on-demand treatment as the sole medicinal', 'management for their HAE during the study. The informed consent and assent for this study will', 'inform subjects on available prophylactic therapies and will note that they cannot discontinue', 'prophylaxis for the sole purpose of screening for the trial; there must be medical and personal', 'choice reasons to do so. If a subject has voluntarily discontinued prophylactic therapy outside', 'of', 'the specified window (see below) in advance of the Screening visit for medical or personal', 'choice reasons, then they may be screened for study eligibility.', 'Use of androgens or tranexamic acid for prophylaxis of HAE attacks is not allowed within', '28 days of the screening visit; C1-INH prophylaxis is not permitted within 14 days of the', 'screening visit. Initiation of any of these prophylactic medications is not allowed during the', 'study.', 'The stipulated timeframe in advance of screening is intended to allow stabilization of the', 'angioedema event rate after discontinuing prophylactic therapies before prospective collection of', 'angioedema events required for eligibility and for the baseline angioedema event rate, which', 'begins at screening. However, it should be noted that subjects may receive approved C1-INH', 'therapies for acute treatment of angioedema attacks, if available, at any time.', '5.4.5.', 'BCX7353 Benefit-Risk Analysis', 'Given that BCX7353 is a small molecule kallikrein inhibitor with safety data available from', 'completed and ongoing Phase 1, 2, and 3 studies, there is an acceptably low risk of severe or', 'serious adverse reactions. Potential risks and findings from nonclinical and clinical studies of', 'BCX7353 are discussed in Section 6 of the IB (Summary of Data and Guidance for the', 'Investigators).', '34']\n\n###\n\n", "completion": "END"}